Use of CGM in Kidney Transplant Recipients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Davis
About this trial
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Eligibility criteria
Qualifiers
Age 18 or above
Received a kidney transplant within the past year with functioning kidney (eGFR > 30 mL/min
Person with Type 2 Diabetes and on insulin
Access to home wi-fi connection
Disqualifiers
Person with Type 1 Diabetes
Patients taking hydroxyurea
Patient unable to wear the Dexcom G6 device at all times for any reason
Must be able to test blood glucose with meter 4x a day when on blinded CGM.
Trial design
Treatments tested in this trial
- Dexcom G6
- Dexcom G6 blinded sensor
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, Davis
Lead sponsor
DexCom, Inc.
Collaborator
Source ClinicalTrials.gov